{"url_path":"/sec/prld/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1678660/0001193125-26-343469-index.html","accession_number":"0001193125-26-343469","cik":"0001678660","ticker":"PRLD","issuer_name":"Prelude Therapeutics Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1678660/0001193125-26-343469-index.html","primary_entity_key":"0001678660","primary_entity_name":"Prelude Therapeutics Inc"},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\n \n\n \n\nExhibit\nNumber\n\n \n\nDescription\n\n99.1\n\n \n\n[Press Release dated August 11, 2026](prld-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL Document)\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\nPRELUDE THERAPEUTICS INCORPORATED\n\n \n\n \n\n \n\n \n\n \n\nDate: August 11, 2026\n\nBy:\n\n/s/ Bryant Lim\n\n \n\n \n\nBryant Lim\n\n \n\n \n\nChief Financial Officer and Chief Legal Officer"}